SCHEDULE: FMR LLC Reports 6.6% Stake in Ascendis Pharma

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 6.6% of Ascendis Pharma AS common stock as of March 31, 2026.

Summary

• FMR LLC, along with its subsidiaries and affiliates (collectively, the "FMR Reporters"), has filed a Schedule 13G, indicating beneficial ownership of Ascendis Pharma AS common stock.
• The filing, dated March 31, 2026, shows that FMR LLC beneficially owns 3,852,100.98 shares, representing 6.6% of the class.
• Abigail P. Johnson, CEO of FMR LLC, is also listed as a reporting person, with the same beneficial ownership attributed to her.
• The filing clarifies that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
• Several entities within FMR LLC, including FIAM LLC, Fidelity Management & Research Company LLC, and Strategic Advisers LLC, are identified as entities that beneficially own 5% or greater of the security class.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of beneficial ownership, indicating investment without providing operational or financial performance details that would suggest a strong positive or negative sentiment.

Positives

• FMR LLC's significant stake indicates confidence in Ascendis Pharma AS.
• The filing is a routine disclosure, suggesting no immediate change in control or activist intent.

Negatives

• No specific financial performance or operational updates are provided in this filing, as it is a beneficial ownership disclosure.

Risks

• The filing does not detail specific risks related to Ascendis Pharma AS's operations or market position.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Ascendis Pharma AS's future performance.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares."
• "Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC."
• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect..."

Industry Context

StockSavvy.ai notes that large institutional investors like FMR LLC filing Schedule 13G reports are common in the biotechnology and pharmaceutical sectors, reflecting significant investment in companies with high growth potential and R&D pipelines. This filing indicates FMR LLC's continued interest in Ascendis Pharma AS.

Corporate Governance

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively for stability and potential future support.
• Management of Ascendis Pharma AS: The disclosure may signal continued interest from FMR LLC, potentially influencing strategic discussions.
• Competitors: The substantial stake by a major investment firm highlights Ascendis Pharma AS as a significant player in its sector.

Next Steps

• FMR LLC will continue to hold its beneficial ownership stake in Ascendis Pharma AS.
• Further filings will be made if ownership levels change significantly.

Key Dates

Keywords

Ascendis Pharma AS, FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, Fidelity, Investment Management, SEC Filing